Research & Publications
Endometrial Cancer: Medicare FFS HCRU Therapy Treatment Study
Summary
This retrospective analysis of the 100% Medicare Fee-for-Service database and Inovalon’s MORE² Registry® of closed claims examined healthcare utilization and costs among 2,484 patients with advanced endometrial cancer who initiated a first line of systemic therapy and later received a second line. Patients were categorized by treatment-free interval — the time between the end of first-line treatment and the start of second-line treatment — to assess the relationship between time to progression and healthcare burden.
Key Findings
- Rapid progression was common: Most patients (85%) had a treatment-free interval of less than six months, suggesting faster disease progression and the need for subsequent therapy.
- Higher burden with faster progression: Patients with a treatment-free interval < 6 months had greater healthcare utilization and higher cancer-related costs than those with > 6 months between treatments.
- Real-world insights: Analysis of national claims data demonstrated that shorter treatment-free intervals were independently associated with higher cancer-specific costs, even after adjusting for patient characteristics.
Why This Matters
Findings from this real-world data analysis underscore the considerable clinical and economic burden among patients with advanced endometrial cancer who experience rapid progression following first-line therapy. These insights highlight the potential for more effective and tolerable initial treatments to help delay disease progression, reduce downstream healthcare use, and mitigate overall costs.
Read the Full Study:
